Don’t know Ganbaatar. We should know a lot
more soon when the P3 results are released. They
say late 2021, but when are biotech trial results
ever on time. Maybe their trials are not as
robust as FDA would like. Seem to be trying to
establish a bridgehead in east Asia.
As you say, Lorecivivint probably won’t be as
effective as iPPS, but are likely to be lot
earlier to market, at least in some parts of the
world.
Don’t know Ganbaatar. We should know a lotmore soon when the P3...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $202.2K | 814.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 181098 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 118621 | 5 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |